Biotech
Prim Increases Turnover by 15% in the First Quarter of 2023, Up to €54 Million
Prim aims to achieve sales of €305 million by 2025. The company founded in 1870 expects that by that date 25% of its business will come from exports, focusing on the European market, especially on Italy and Portugal, as well as disembarking on the Asian continent in the markets of China and Japan. In 2022, the Madrid group increased its turnover by 17%, up to €197 million.
![](https://born2invest.com/wp-content/uploads/2023/05/euro-g03f1440dd_1280.jpg)
Prim grows in billing and benefits. The Spanish company invoiced €54 million in the first quarter of the year, which translates into a year-on-year increase of 15%, according to the company in a statement.
The increase in the company’s turnover is due to the increase in its business segment, which has led to a 9% rise in both the company’s product portfolio and the results of the companies acquired by the company as part of the plan strategic 2021-2025.
The group has increased the gross margin on sales to 49.1%, compared to 47.1% in the same period of the previous year, a rebound that has arisen as a result of the increase in the price of some products that has generated higher margins. The total amount of gross margin reached €26.8 million in the first quarter of 2023.
Prim presented an EBITDA of €6.6 million in the first quarter of the year, which represents a year-on-year increase of 20.8%. Meanwhile, the operating result increased by 25% in the same period compared to the previous year, up to €4.4 million.
If you want to find more details about Prim and its latest financial results, download for free our companion app. The Born2Invest mobile app brings you the most important business news of the day, so you can stay informed.
Prim expects to reach €305 million in sales by 2025
The company’s investments in 2022 resulted in the acquisition of companies in order to increase the group’s efficiency. This is how until March 2023 the investment results have shown a positive reflection.
Among Prim’s latest movements, the sale in February of the Spa segment, specializing in the construction of spas, stands out as part of the company’s strategic plan to improve the group’s financial situation and reinforce growth in the medical technology segments. and in the area of mobility and health care.
Prim aims to achieve sales of €305 million by 2025. The company founded in 1870 expects that by that date 25% of its business will come from exports, focusing on the European market, especially on Italy and Portugal, as well as disembarking on the Asian continent in the markets of China and Japan.
In 2022, the Madrid group increased its turnover by 17%, up to €197 million, while the company’s net profit reached 8.4 million, which represented a year-on-year decrease of 72%, due to the revaluation of the dollar.
__
(Featured image by geralt via Pixabay)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Born2Invest, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
![](https://born2invest.com/wp-content/uploads/2018/11/logo-slogan.png)
-
Africa4 days ago
Despite a Population Four Times Smaller, Algeria Should Overtake Nigeria in 2024
-
Impact Investing1 week ago
Enfinity Global Inc (Icg) Gets $500M Funding to Build Solar Plants in Italy
-
Crowdfunding2 days ago
Nuvola Zero Launches an Equity Crowdfunding Campaign with a Collection Target of 1.5 Million
-
Crypto1 week ago
OpenSea Challenged by US Securities and Exchange Commission (SEC)